Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stenoparib and Temozolomide in Relapsed SCLC
NCT06681220Phase 2Recruiting
- Sponsor
- VA Office of Research & Development
- Start
- Feb 2026
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of stenoparib in small cell lung cancer (SCLC) (4 arms), sponsored by VA Office of Research & Development. Primary endpoints: Progression Free Survival at 2 years and Recommended Phase 2 dose at 21 days. Started Feb 2026; status: recruiting.
02
Drugs
stenoparib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06681220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06681220.